Skip To Main Content
B. Cabarrou on Muck Rack

B. Cabarrou

As seen in: Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with B.

Contact B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

How to report toxicity associated with targeted therapies?

|
By B. Cabarrou, Institut Claudius Régaud, IUCT-O Toulouse, J. M. Boher, Institut Paoli Calmette
| Annals of Oncology Verified
Background In the era of personalized medicine, molecularly targeted therapies (MTT) have modified the outcome of some cancer types. The price of tumor control needs to be balanced with toxicity since these new therapies are administered continuously for several months or sometimes for several years. For cytotoxic drugs, the incidence of adverse event (AE) was traditionally reported as frequency and intensity. This simple measure is not sufficient to capture the recurrent nature and duration of AE.
Open in Who Shared Issue with article?

How to report toxicity associated with targeted therapies?

|
By Institut Claudius Régaud, Institut Paoli Calmette, B. Cabarrou, IUCT-O Toulouse, J. M. Boher
| Annals of Oncology Verified
Background In the era of personalized medicine, Molecularly Targeted Therapies (MTT) has modified the outcome of some cancer types. The price of tumour control needs to be balanced with toxicity since these new therapies are administered continuously for several months or sometimes for several years. For cytotoxic drugs, the incidence of adverse event (AE) was traditionally reported as frequency and intensity. This simple measure is not sufficient to capture the recurrent nature and duration of AE.
Open in Who Shared Issue with article?
See all 2 articles